Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cilazapril. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE known ✓ | P12821 | 13/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | MME | P08473 | 2/20 | 0.55 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.55 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.55 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cilazapril SCHEMBL14287315 | 1.00 | ACE (0.76) | ACELMNAMMEABCB11AGTR2 | |
| Cilazapril SCHEMBL16290008 | 1.00 | ACE (0.76) | ACELMNAMMEABCB11AGTR2 | |
| Cilazapril SCHEMBL29394939 | 1.00 | ACE (0.76) | ACELMNAMMEABCB11AGTR2 | |
| Cilazapril SCHEMBL10368731 | 1.00 | ACE (0.76) | ACELMNAMMEABCB11AGTR2 | |
| Cilazapril SCHEMBL10562310 | 0.99 | ACE (0.75) | ACELMNAMMEABCB11AGTR2 | |
| Cilazapril SCHEMBL19469323 | 0.99 | ACE (0.75) | ACELMNAMMEABCB11AGTR2 | |
| Cilazapril SCHEMBL15263655 | 0.99 | ACE (0.75) | ACELMNAMMEABCB11AGTR2 | |
| Cilazapril SCHEMBL136488 | 0.99 | ACE (0.75) | ACELMNAMMEABCB11AGTR2 | |
| Cilazapril SCHEMBL24961 | 0.99 | ACE (0.75) | ACELMNAMMEABCB11AGTR2 | |
| Cilazapril SCHEMBL6508385 | 0.99 | ACE (0.75) | ACELMNAMMEABCB11AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 19866 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| EP-4731194-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT | CSP Technologies, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| US-12605345-B2 | Transdermal drug delivery system | BioPhysics Pharma, Inc. (US) | 2026-04-21 | — | — | US | claimed |
| EP-4710928-A2 | METHODS OF TREATING IGA NEPHROPATHY WITH ATRASENTAN | Chinook Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | claimed |
| EP-4687805-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING ACTIVATED CARBON OR A DERIVATIVE THEREOF | CSP Technologies, Inc. (US) | 2026-02-11 | — | — | EP | claimed |
| US-20260027008-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING ACTIVATED CARBON OR A DERIVATIVE THEREOF | CSP TECHNOLOGIES, INC. | 2026-01-29 | — | — | US | claimed |
| EP-4674894-A2 | COPOLYMERS OF N-VINYLPYRROLIDONE WITH FUNCTIONALIZED MALEIC ACID MOIETIES | Hemoteq AG (DE) | 2026-01-07 | — | — | EP | claimed |
| WO-2025264260-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT | CSP TECHNOLOGIES, INC. (US) | 2025-12-26 | — | — | WO | claimed |
| EP-4663688-A2 | CROSSLINKERS | Hemoteq AG (DE) | 2025-12-17 | — | — | EP | claimed |
| EP-4076652-B1 | A PHARMACEUTICALLY ACCEPTABLE SALT OF ATRASENTAN FOR USE IN A METHOD OF TREATING IGA NEPHROPATHY | CHINOOK THERAPEUTICS INC (US) | 2025-12-03 | — | — | EP | claimed |
| EP-0351017-A2 | Pharmaceutical composition useful for the treatment of cardiovascular diseases | ZAMBON GROUP S.p.A. (IT) | 1990-01-17 | — | — | EP | claimed |
| EP-0336950-A1 | POTENTIATION OF ANTIHYPERTENSIVE EFFECT OF ACE INHIBITORS | CIBA-GEIGY AG (CH) | 1989-10-18 | — | — | EP | claimed |
| US-4859665-A | Antihypertensive combination products containing a dihydropyridine and a pyridazodiazepine | HOFFMANN-LAROCHE INC. (US) | 1989-08-22 | — | — | US | claimed |
| EP-0224810-B1 | ANTIHYPERTENSIVE PREPARATION CONTAINING A MIXTURE | BAYER AG (DE) | 1989-07-19 | — | — | EP | claimed |
| EP-0320097-A1 | Controlled absorption diltiazem formulations | ELAN CORPORATION, Plc (IE) | 1989-06-14 | — | — | EP | claimed |
| WO-1989003691-A1 | POTENTIATION OF ANTIHYPERTENSIVE EFFECT OF ACE INHIBITORS | CIBA-GEIGY AG (CH) | 1989-05-05 | — | — | WO | claimed |
| EP-0272177-A1 | Pharmaceutical composition containing diltiazem and an inhibitor of the enzyme-transforming angiotensin | SYNTHELABO (FR) | 1988-06-22 | — | — | EP | claimed |
| EP-0254032-A2 | Neutral metalloendopeptidase inhibitors in the treatment of hypertension | SCHERING CORPORATION (US) | 1988-01-27 | — | — | EP | claimed |
| EP-0220107-A2 | Use of angiotensin-converting enzyme inhibitors in macular degeneration | MERCK & CO. INC. (US) | 1987-04-29 | — | — | EP | claimed |
| US-4656188-A | Ace inhibitors in macular degeneration | MERCK & CO., INC. (US) | 1987-04-07 | — | — | US | claimed |